Bariatric Surgery Lowers Cancer Risk at Every Age, For Men and Women Alike: What a 780,000-Person Nordic Study Found
Bariatric Surgery Lowers Cancer Risk at Every Age, For Men and Women Alike: What a 780,000 Person Nordic Study Found One of the most frequent questions I hear from patients…
Bariatric Surgery Lowers Cancer Risk at Every Age, For Men and Women Alike: What a 780,000-Person Nordic Study Found
One of the most frequent questions I hear from patients considering weight-loss surgery is whether the benefits are really worth it beyond the number on the scale. A large new study published online on October 14, 2026, in JAMA Surgery gives one of the clearest answers yet, and it strengthens a message I give patients often: bariatric surgery is not just a cosmetic or metabolic intervention, it is a cancer-prevention intervention.
A study built on real-world, national-scale data
Researchers at the Karolinska Institutet, led by Dr. Cecilia Radkiewicz, analyzed data from more than 780,000 people living with obesity across Sweden, Denmark, and Finland. Roughly 100,000 of them had undergone bariatric surgery, most commonly gastric bypass or sleeve gastrectomy. By linking national health registries, the team was able to compare cancer incidence between those who had surgery and those who did not, across a wide range of ages and in both sexes.
This kind of registry-based design has a real strength: because Nordic countries maintain near-complete, long-running national health records, this study avoids much of the recall bias and loss-to-follow-up that weakens many smaller surgical cohorts. It is one of the largest analyses of its kind ever conducted.
What the researchers found
Across the entire cohort, people who underwent bariatric surgery had an approximately 20% lower risk of developing an obesity-related cancer compared with people with obesity who were treated without surgery. Obesity-related cancers include cancers of the liver, endometrium (uterine lining), ovary, kidney, colon, and several others where excess body fat is a recognized driver of cancer development through chronic inflammation, insulin resistance, and altered sex-hormone metabolism.
What makes this study particularly reassuring is what the researchers did not find: no evidence that the protective effect of surgery differed meaningfully by age at the time of surgery, and no evidence that it differed between men and women for cancers that affect both sexes. In other words, the benefit was not confined to younger patients or to women undergoing surgery before menopause, as some earlier, smaller studies had suggested it might be. The reduction in risk held up consistently across the age spectrum represented in the cohort. The largest relative reductions were observed for liver, endometrial, and ovarian cancers, consistent with the biological mechanisms linking excess visceral fat to these particular tumor types.
Why this matters for how we counsel patients
For years, the conversation around bariatric surgery's cancer benefit has been slightly hedged, because much of the supporting evidence came from populations skewed toward middle-aged women, leaving open the question of whether older patients or men would see the same advantage. This study, by virtue of its sheer size and national scope, closes much of that gap.
Clinically, this reframes how I discuss surgery with patients who are on the fence, particularly those in their 50s and 60s who sometimes assume that surgery's benefits are mainly relevant to younger people planning decades of healthier life ahead. The data suggest that reducing the metabolic burden of excess fat still meaningfully lowers cancer risk even when surgery is performed later in life, likely because chronic inflammation and insulin resistance continue driving cancer risk at any age, and removing that driver still matters.
A caveat worth stating plainly
This remains an observational study, not a randomized trial, so it cannot fully exclude the possibility that people who choose and qualify for surgery differ in other health-related ways from those who do not. However, the consistency of the effect across such a large, demographically varied population, and its alignment with known biological mechanisms, makes this a meaningfully strong piece of evidence rather than a preliminary signal.
For patients, the takeaway is straightforward: the cancer-risk reduction associated with bariatric surgery is not a side benefit reserved for a particular age group or sex. It appears to be a durable, broadly applicable effect of treating obesity surgically, one more reason this remains among the most effective tools we have for a disease with far-reaching, often underappreciated health consequences.
Source: Radkiewicz C, et al. JAMA Surgery, published online October 14, 2026 (DOI: 10.1001/jamasurg.2026.4798).
Related articles
8 in 10 Tumors Responded: Early Results for a New Targeted Combination in a Common Pancreatic Cancer Mutation
8 in 10 Tumors Responded: Early Results for a New Targeted Combination in a Common Pancreatic Cancer Mutation Response rates in metastatic pancreatic cancer have historically been…
Bariatric Surgery and Cancer Risk: What 33 Years of Follow-Up in the Swedish Obese Subjects Study Reveal
When I counsel patients considering bariatric surgery, most of the conversation naturally centers on diabetes remission, blood pressure, joint pain, and quality of life. Cancer…
Six Years Out: What the Longest Follow-Up Yet on a Pancreatic Cancer mRNA Vaccine Shows
Pancreatic cancer remains one of the most difficult cancers I treat, largely because even after a successful, complete surgical resection, the majority of patients eventually…
Have questions about your own health?
Ask the AI Knowledge Center — trained on Professor Jamal's own publications and guidelines — or book a consultation in person.